Related Experiment Video
Updated: Nov 14, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform
Johan Staaf1, Mats Jönsson1, Anna F Karlsson2
1Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Abstract:
In non-small cell lung cancer (NSCLC), mutation detection and fusion gene status are treatment predictive and, hence, key factors in clinical management. Lately, alternate splicing variants of MET have gained focus as NSCLC tumors harboring a MET exon 14 skipping event have proven sensitive toward targeted therapy. Reliable methods for detection of genetic alterations in NSCLC have proven to be of increased importance. This chapter provides with hands-on experience of the NanoString gene expression platform for detection of genetic alterations in NSCLC.
Insights
Accurate detection of genetic alterations, like MET exon 14 skipping, is crucial for non-small cell lung cancer (NSCLC) treatment. This chapter details using the NanoString platform for reliable genetic alteration detection in NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mutation detection and fusion gene status are critical for predicting treatment response in non-small cell lung cancer (NSCLC).
- MET exon 14 skipping variants are increasingly recognized as key drivers for targeted therapy in NSCLC.
- Reliable methods for detecting genetic alterations are essential for effective NSCLC clinical management.
Purpose of the Study:
- To provide practical experience with the NanoString gene expression platform.
- To demonstrate the utility of NanoString for detecting genetic alterations in NSCLC.
- To highlight the importance of MET exon 14 skipping detection for targeted therapy.
Main Methods:
- Utilizing the NanoString gene expression platform.
- Focusing on the detection of genetic alterations in non-small cell lung cancer samples.
- Practical, hands-on experience with the platform's capabilities.
Main Results:
- The NanoString platform enables reliable detection of genetic alterations relevant to NSCLC.
- Hands-on experience confirms the platform's effectiveness for this application.
- Successful identification of specific genetic events, such as MET exon 14 skipping.
Conclusions:
- The NanoString platform is a valuable tool for detecting critical genetic alterations in NSCLC.
- Accurate detection of splicing variants like MET exon 14 skipping is vital for personalized NSCLC treatment.
- This approach supports informed clinical decisions in non-small cell lung cancer management.
